

Mumbai, 11th July 2025

Wockhardt Initiates Strategic Realignment of US Operations to Focus on Innovative Portfolio

Wockhardt is undertaking significant strategic realignment of its US business in line with its long-term vision to build a differentiated, innovation-driven pharmaceutical enterprise. As part of this transition, the Company has taken decision to exit the US generic pharmaceutical segment, paving the way for deeper focus and investment in its advanced product portfolio.

This strategic reset aligns with Wockhardt's sharpened focus on building a future-ready business anchored in two key pillars:

1. **New Antibiotic Drug Discovery** – where Wockhardt has established a leadership position globally, with a strong pipeline of differentiated assets.
2. **Biologicals Portfolio in Insulin** – leveraging advanced technologies to address critical unmet needs in diabetes care.

Over the past several years, Wockhardt's US generics business has been incurring losses. In FY 2025 alone, the generics business incurred a loss of nearly USD 8 million. Following a comprehensive strategic review, the Company has concluded that continuing in this segment would detract from its broader innovation agenda.

Accordingly, Wockhardt has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its US step down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, both incorporated in Delaware which are wholly owned subsidiaries of Wockhardt Bio AG. This decision, effective 11 July 2025, enables a clean and structured exit from a legacy segment and unlocks management bandwidth and capital for high-impact areas.

By stepping away from the commoditized generics space, Wockhardt is positioning itself to create long-term value through innovation, scientific excellence, and sustainable profitability. The Company remains committed to its pharmaceutical operations in India, the UK, Ireland, and other geographies where its businesses continue to deliver strong performance.

This strategic evolution marks a decisive move toward a more focused, resilient, and innovation-led Wockhardt, better equipped to deliver value to patients, partners, and shareholders in the years ahead.

About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.



Wockhardt Limited

Registered Office:

D-4, MIDC, Chikalthana

Chhatrapati Sambhajnagar

431006, India

Tel.: +91-22-2653 4444

CIN: L24230MH1999PLC120720

www.wockhardt.com**PRESS RELEASE****WOCKHARDT** | **LIFE WINS**

Wockhardt is employing around ~2900 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in Europe and India, with ~77% of its global revenues coming from international businesses.